Drug facts

Tirzepatide, surgery and sedation

By ·Editor·Reviewed

Quick answer

Slower stomach emptying is also discussed in the guide to drug interactions because it can affect how oral medicines are absorbed. The label carries a separate warning about it: there have been rare reports of stomach contents entering the lungs during general anesthesia or deep sedation, in people who reported following their fasting instructions. The label then says the available data are not enough to say what to do about it — including whether stopping the drug beforehand would help. What it does instruct is unambiguous: tell your healthcare providers you are taking it, before any planned surgery or procedure.

What the label reports1

Section 5.9 of the approved tirzepatide label describes rare postmarketing reports of pulmonary aspiration — stomach contents reaching the lungs — in patients taking GLP-1 receptor agonists who underwent elective surgeries or procedures requiring general anesthesia or deep sedation.

The detail that makes it a warning rather than a footnote is this: it happened in people who had “residual gastric contents despite reported adherence to preoperative fasting recommendations”. In other words, the usual instruction to stop eating some hours beforehand did not reliably leave the stomach empty.

The label says it does not know1

This is the part worth reading slowly, because it is unusual for a label to be this direct about the limits of what it can tell you:

Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking ZEPBOUND, including whether modifying preoperative fasting recommendations or temporarily discontinuing ZEPBOUND could reduce the incidence of retained gastric contents.

So the label raises the risk and then declines to prescribe a way around it. It does not say to stop the drug before a procedure. It does not say to fast for longer. It says nobody yet has the evidence to know whether either would help. Any confident rule you find elsewhere — a set number of days to hold, a specific fasting window — did not come from this document, and it is worth knowing that before you act on it.

Why it happens at all2

Tirzepatide delays gastric emptying — the label states it plainly, and it is part of how the drug works rather than a side effect of it. Food leaves the stomach more slowly, which is also why the same mechanism can affect how other medicines taken by mouth are absorbed.

One nuance from the same section is worth carrying: the effect on gastric emptying was greatest after a single 5 mg dose and diminished after subsequent doses. The slowing is most pronounced early rather than accumulating over time — which is a fact about the average of a studied group, not a prediction about any particular stomach on any particular morning.

Severe gastroparesis is a separate line3

Inside the warning about severe gastrointestinal reactions, the label adds one sentence that is easy to miss because it is not a heading of its own: tirzepatide is not recommended in patients with severe gastroparesis. Gastroparesis is a condition in which the stomach already empties too slowly. A drug whose action is to slow it further is not recommended on top of it.

On the label — Mounjaro / Zepbound

Carries section 5.9 in the document dispensed with it, and the Medication Guide that goes to the patient repeats the instruction to tell healthcare providers about planned procedures.

In a compounded vial

Tell the team what you are taking even if it came from a compounding pharmacy. The Zepbound label describes the approved product; it does not establish how a specific compounded formulation behaves.

The one instruction the label does give1

After declining to recommend a mitigation, the label ends section 5.9 with something concrete: “Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking ZEPBOUND.”

That covers more than an operation. Deep sedation is used for endoscopy, colonoscopy, some dental work and a range of outpatient procedures, and the person who needs to know is the one giving the sedation, not only the one who prescribed the tirzepatide. If you take it, say so when a procedure is booked and again on the day — including when the vial came from a compounding pharmacy rather than a prescription for a branded pen.

Related: what the label reports and how often · what the label says about other medicines

Sources

  1. FDA prescribing information for ZEPBOUND (tirzepatide), section 5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation, revision 8/2026 DailyMed
  2. FDA prescribing information for ZEPBOUND (tirzepatide), sections 12.2 Pharmacodynamics and 12.3 Pharmacokinetics, revision 8/2026 DailyMed
  3. FDA prescribing information for ZEPBOUND (tirzepatide), section 5.2 Severe Gastrointestinal Adverse Reactions, revision 8/2026 DailyMed